Evidence map›Paper›PMID 32070354›Full record

ArticleJournal of nanobiotechnology2020

Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms.

Leisha M Armijo, Stephen J Wawrzyniec, Michael Kopciuch, Yekaterina I Brandt, Antonio C Rivera, Nathan J Withers, Nathaniel C Cook, Dale L Huber, Todd C Monson, Hugh D C Smyth and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 169 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Leisha M ArmijoCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Stephen J WawrzyniecCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Michael KopciuchCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Yekaterina I BrandtCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Antonio C RiveraCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Nathan J WithersCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Nathaniel C CookCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA.
Dale L HuberCenter for Integrated Nanotechnologies, Sandia National Laboratories, 1000 Eubank SE, Albuquerque, NM, 87123, USA.
Todd C MonsonSandia National Laboratories, Nanomaterials Sciences, P.O. Box 5800, MS 1415, Albuquerque, NM, 87185, USA.
Hugh D C SmythCollege of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Stop A1900, Austin, TX, 78712, USA.
Marek OsińskiCenter for High Technology Materials, University of New Mexico, 1313 Goddard Street SE, Albuquerque, NM, 87106-4343, USA. osinski@chtm.unm.edu.ORCID http://orcid.org/0000-0002-3989-991X
University of New Mexico · USSandia National Laboratories · USSandia National Laboratories California · USThe University of Texas at Austin · US

Funding

UNM Initiative to Maximize Student Diversity (IMSD)R25GM060201 · NIGMS · UNIVERSITY OF NEW MEXICO · PI WERNER-WASHBURNE, MARGRET C. · 2000 to 2017
$9.9M
NIGMS NIH HHS R25 GM060201NIH HHS 1R21HL092812-01A1NIH HHS GM-060201
6 · The paper itself

Abstract

backgroundNovel methods are necessary to reduce morbidity and mortality of patients suffering from infections with Pseudomonas aeruginosa. Being the most common infectious species of the Pseudomonas genus, P. aeruginosa is the primary Gram-negative etiology responsible for nosocomial infections. Due to the ubiquity and high adaptability of this species, an effective universal treatment method for P. aeruginosa infection still eludes investigators, despite the extensive research in this area.

resultsWe report bacterial inhibition by iron-oxide (nominally magnetite) nanoparticles (NPs) alone, having a mean hydrodynamic diameter of ~ 16 nm, as well as alginate-capped iron-oxide NPs. Alginate capping increased the average hydrodynamic diameter to ~ 230 nm. We also investigated alginate-capped iron-oxide NP-drug conjugates, with a practically unchanged hydrodynamic diameter of ~ 232 nm. Susceptibility and minimum inhibitory concentration (MIC) of the NPs, NP-tobramycin conjugates, and tobramycin alone were determined in the PAO1 bacterial colonies. Investigations into susceptibility using the disk diffusion method were done after 3 days of biofilm growth and after 60 days of growth. MIC of all compounds of interest was determined after 60-days of growth, to ensure thorough establishment of biofilm colonies.

conclusionsPositive inhibition is reported for uncapped and alginate-capped iron-oxide NPs, and the corresponding MICs are presented. We report zero susceptibility to iron-oxide NPs capped with polyethylene glycol, suggesting that the capping agent plays a major role in enabling bactericidal ability in of the nanocomposite. Our findings suggest that the alginate-coated nanocomposites investigated in this study have the potential to overcome the bacterial biofilm barrier. Magnetic field application increases the action, likely via enhanced diffusion of the iron-oxide NPs and NP-drug conjugates through mucin and alginate barriers, which are characteristic of cystic-fibrosis respiratory infections. We demonstrate that iron-oxide NPs coated with alginate, as well as alginate-coated magnetite-tobramycin conjugates inhibit P. aeruginosa growth and biofilm formation in established colonies. We have also determined that susceptibility to tobramycin decreases for longer culture times. However, susceptibility to the iron-oxide NP compounds did not demonstrate any comparable decrease with increasing culture time. These findings imply that iron-oxide NPs are promising lower-cost alternatives to silver NPs in antibacterial coatings, solutions, and drugs, as well as other applications in which microbial abolition or infestation prevention is sought.

Indexed as

AlginatesAnti-Bacterial AgentsBiofilmsCystic FibrosisDrug CarriersDrug DesignDrug Therapy, CombinationFerric CompoundsHumansMagnetic FieldsMagnetite NanoparticlesMicrobial Sensitivity TestsParticle SizePseudomonas aeruginosaPseudomonas InfectionsSilverAlginatesAnti-Bacterial Agentscolloidal silverDrug CarriersFerric Compoundsferric oxideMagnetite NanoparticlesSilverTobramycinAlginateAntibacterial agentsAntibiotic resistanceBiofilmCystic fibrosisDrug deliveryIron-oxide nanoparticlesMagnetitePseudomonas aeruginosaZero-valent iron nanoparticles

Identifiers

PMID32070354
PMCPMC7029462
OpenAlexW3012679410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.